Published in Cancer Weekly, August 30th, 1999
In preclinical models, prinomastat has been shown to potently inhibit angiogenesis, tumor invasion, and metastasis. This trial is designed to evaluate the safety and efficacy of prinomastat as part of first-line therapy in combination with chemotherapy, an effort led by ongoing Phase III clinical trials. This trial advances the ongoing clinical development of prinomastat in combination with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.